

Supplementary Table 4. Subgroup analysis of quality of life and subjectively judgement for the treatment efficacy

	SNOT-22 scores after 3 months	SNOT-22 scores after 6 months	Much or very much improvements in PGIC scores after 3 months	Much or very much improvements in PGIC scores after 6 months
Overall symptoms score	MD -8.9811, 95% CI [-11.1230; -6.8393]; I ² =0.0%	MD -5.3347, 95% CI [-7.9059; -2.7635]; I ² =56.6%	MD 3.5066, 95% CI [2.6629; 4.6177]; I ² =0.0%	MD 1.8511, 95% CI [1.1310; 3.0298]; I ² =77.2%
93 µg	n=2 MD -8.5622, 95% CI [-12.2711; -4.8534]; I ² =0.0%	n=2 MD -2.1534, 95% CI [-5.9341; 1.6273]; I ² =0.0%	n=2 MD 3.2238, 95% CI [2.0065; 5.1796]; I ² =47.8%	n=2 MD 0.8873, 95% CI [0.1821; 4.3231]; I ² =89.0%
186 µg	n=2 MD -9.2456, 95% CI [-12.9741; -5.5170]; I ² =0.0%	n=4 MD -6.0869, 95% CI [-9.6581; -2.5156]; I ² =43.3%	n=2 MD 3.6512, 95% CI [2.2578; 5.9044]; I ² =0.0%	n=4 MD 2.0127, 95% CI [1.0032; 4.0383]; I ² =72.5%
372 µg	n=2 MD -9.1370, 95% CI [-12.8295; -5.4446]; I ² =0.0%	n=4 MD -6.1513, 95% CI [-11.3054; -0.9972]; I ² =72.9%	n=2 MD 3.6681, 95% CI [2.2801; 5.9012]; I ² =0.9%	n=4 MD 2.4588, 95% CI [1.2376; 4.8853]; I ² =69.8%
p value	0.9631	0.2695	0.9128	0.5101

SNOT-22, 22-item Sinonasal Outcome Test; PGIC, Patient Global Impression of change; MD, mean difference; CI, confidence interval.